BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1000 related articles for article (PubMed ID: 16170482)

  • 21. Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group.
    Eich HT; Haverkamp U; Engert A; Kocher M; Skripnitchenko R; Brillant C; Sehlen S; Dühmke E; Diehl V; Müller RP
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):860-5. PubMed ID: 15925455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions.
    Klimm B; Goergen H; Fuchs M; von Tresckow B; Böll B; Meissner J; Glunz A; Diehl V; Eich HT; Engert A; Borchmann P
    Ann Oncol; 2013 Dec; 24(12):3070-6. PubMed ID: 24148816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma.
    Sieniawski M; Franklin J; Nogova L; Glossmann JP; Schober T; Nisters-Backes H; Diehl V; Josting A
    J Clin Oncol; 2007 May; 25(15):2000-5. PubMed ID: 17420510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analyses of patterns-of-failure and prognostic factors according to radiation fields in early-stage Hodgkin lymphoma.
    Krebs L; Amorin S; Brice P; Guillerm S; Menard J; Hennequin C; Quéro L
    Strahlenther Onkol; 2017 Feb; 193(2):116-124. PubMed ID: 27316376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials.
    Böll B; Görgen H; Fuchs M; Pluetschow A; Eich HT; Bargetzi MJ; Weidmann E; Junghanß C; Greil R; Scherpe A; Schmalz O; Eichenauer DA; von Tresckow B; Rothe A; Diehl V; Engert A; Borchmann P
    J Clin Oncol; 2013 Apr; 31(12):1522-9. PubMed ID: 23509310
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
    Diehl V; Fuchs M;
    Transfus Apher Sci; 2007 Aug; 37(1):37-41. PubMed ID: 17714996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transformation in the use of radiation therapy of Hodgkin lymphoma: new concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT).
    Yahalom J
    Eur J Haematol Suppl; 2005 Jul; (66):90-7. PubMed ID: 16007875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.
    Nogová L; Reineke T; Brillant C; Sieniawski M; Rüdiger T; Josting A; Bredenfeld H; Skripnitchenko R; Müller RP; Müller-Hermelink HK; Diehl V; Engert A;
    J Clin Oncol; 2008 Jan; 26(3):434-9. PubMed ID: 18086799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
    Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protection of quality and innovation in radiation oncology: the prospective multicenter trial the German Society of Radiation Oncology (DEGRO-QUIRO study). Evaluation of time, attendance of medical staff, and resources during radiotherapy with IMRT.
    Vorwerk H; Zink K; Schiller R; Budach V; Böhmer D; Kampfer S; Popp W; Sack H; Engenhart-Cabillic R
    Strahlenther Onkol; 2014 May; 190(5):433-43. PubMed ID: 24595416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Radiotherapeutic quality assurance in the Hodgkin's disease study HD4 supported by the BMFT (Bundesministerium für Forschung und Technologie)].
    Roth SL; Dühmke E; Kirschner H; Willich N; Müller RP; Bleher A; Pfreundschuh M; Löffler M; Diehl V
    Strahlenther Onkol; 1990 Sep; 166(9):584-7. PubMed ID: 2120784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiation Dose Reduction in Early-Stage Hodgkin Lymphoma.
    Shah BA; Oh C; Wu SP; Karp JM; Grossbard M; Gerber NK
    Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):820-829. PubMed ID: 32800712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
    Eich HT; Diehl V; Görgen H; Pabst T; Markova J; Debus J; Ho A; Dörken B; Rank A; Grosu AL; Wiegel T; Karstens JH; Greil R; Willich N; Schmidberger H; Döhner H; Borchmann P; Müller-Hermelink HK; Müller RP; Engert A
    J Clin Oncol; 2010 Sep; 28(27):4199-206. PubMed ID: 20713848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Report of the workshop on clinical trials. GHSG. German Hodgkin Study Group.
    Rüffer JU; Sieber M
    Ann Oncol; 1996; 7 Suppl 4():127-9. PubMed ID: 8836423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials.
    Bröckelmann PJ; Goergen H; Kohnhorst C; von Tresckow B; Moccia A; Markova J; Meissner J; Kerkhoff A; Ludwig WD; Fuchs M; Borchmann P; Engert A
    J Clin Oncol; 2017 May; 35(13):1444-1450. PubMed ID: 28240973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiation doses to mediastinal organs at risk in early-stage unfavorable Hodgkin lymphoma- a risk stratified analysis of the GHSG HD17 trial.
    Oertel M; Hering D; Baues C; Kittel C; Fuchs M; Kriz J; Kröger K; Vordermark D; Herfarth K; Engenhart-Cabillic R; Lukas P; Haverkamp U; Borchmann P; Eich HT
    Front Oncol; 2023; 13():1183906. PubMed ID: 37213291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Checkpoint inhibitors and radiation treatment in Hodgkin's lymphoma : New study concepts of the German Hodgkin Study Group.
    Baues C; Semrau R; Gaipl US; Bröckelmann PJ; Rosenbrock J; Engert A; Marnitz S
    Strahlenther Onkol; 2017 Feb; 193(2):95-99. PubMed ID: 27704149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group.
    Eichenauer DA; Plütschow A; Fuchs M; Sasse S; Baues C; Böll B; von Tresckow B; Diehl V; Borchmann P; Engert A
    J Clin Oncol; 2020 Mar; 38(7):698-705. PubMed ID: 31626571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Involved-node radiotherapy in early-stage Hodgkin's lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG).
    Eich HT; Müller RP; Engenhart-Cabillic R; Lukas P; Schmidberger H; Staar S; Willich N;
    Strahlenther Onkol; 2008 Aug; 184(8):406-10. PubMed ID: 18956517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Twenty-year disease and treatment-associated mortality rates of patients with Hodgkin lymphoma of clinical stages IIIB and IV prospectively treated with 3-month anthracycline-based chemotherapy followed by extended high-dose radiation.
    Sénécal D; Jais JP; Desablens B; Berthou C; Casassus P; Moles MP; Delwail V; Gastinne T; Colonna P; Andrieu JM
    Cancer; 2008 Feb; 112(4):846-55. PubMed ID: 18072259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.